ArticleJournal of clinical biochemistry and nutrition2009
The Role of RANTES Promoter Polymorphism in Functional Dyspepsia.
Article in Journal of clinical biochemistry and nutrition, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Immune Activation in Functional Gastrointestinal Disorders.Gastroenterology & hepatology · 2019Article
- Gene Polymorphisms and Susceptibility to Functional Dyspepsia: A Systematic Review and Meta-Analysis.Gastroenterology research and practice · 2019Review
- Immunopathological and molecular basis of functional dyspepsia and current therapeutic approaches.Expert review of clinical immunology · 2018Review
- Genetic variants of immune-related genes IL17F and IL10 are associated with functional dyspepsia: A case-control study.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2017Article
- Gene polymorphisms associated with functional dyspepsia.World journal of gastroenterology · 2015Review
- Helicobacter pylori and functional dyspepsia: an unsolved issue?World journal of gastroenterology · 2014Review
- Functional Dyspepsia in Review: Pathophysiology and Challenges in the Diagnosis and Management due to Coexisting Gastroesophageal Reflux Disease and Irritable Bowel Syndrome.Gastroenterology research and practice · 2013Article
- Serotonin receptor 3A polymorphism c.-42C > T is associated with severe dyspepsia.BMC medical genetics · 2011Article
- Serotonin transporter gene polymorphism may be associated with functional dyspepsia in a Japanese population.BMC medical genetics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Altered inflammatory immune responses have been shown to be associated with functional gastro intestinal disorder. We aimed to clarify the effect of functional promoter polymorphism of RANTES, which is a potent chemoattractant peptide for memory T lymphocytes and eosinophils, on the risk of functional dyspepsia in a Japanese population. RANTES promoter C-28G polymorphism was genotyped in 246 subjects including 134 FD patients according to Roma III criteria and 112 non-symptomatic healthy controls. Although frequency of RANTES promoter polymorphisms in overall dyspeptic patients and non-symptomatic healthy controls did not show any significant differences, a significant association was found between G carrier and reduced risk of PDS according to Roma III criteria (age, sex, H. pylori infection adjusted OR = 0.23, 95% CI = 0.06-0.80). We also found that the same genotype held a lower risk of PDS in H. pylori positive PDS subjects (age, sex adjusted OR = 0.11, 95% CI = 0.01-0.94). Our data suggest that RANTES promoter -28G carriers is associate with a reduced risk of PDS especially in H. pylori positive subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.